Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma's Eric Pauwels, who's launched five ultra-rare disease products, explains how these biotech brands can demonstrate their value. Marc Iskowitz reports
The estimated cost savings for only 10% of participants changing their practice is somewhere in the million-dollar range, according to a study.
Quarterly reports show that that the weight loss category remains a cool one, but studies indicate that even the best marketing plan will have to overcome payer and pricing issues.
Roche's oncology trifecta of Herceptin, Avastin and mabThera/Rituxan buoyed quarterly sales. Devices and diagnostics sales were solid, if less impressive.
Solo practitioners favor Mitt Romney over Barack Obama by a two-to-one ratio, a survey finds, suggesting that changes in reimbursement driven by Obamacare are driving physicians' presidential preferences.